These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16197491)

  • 1. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
    Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
    Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW; Hahm KB; Kim JH
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
    Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
    Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.
    Buti M; Jardi R; Rodriguez-Frias F; Valdes A; Schaper M; Esteban R; Guardia J
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1349-56. PubMed ID: 15932365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
    J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
    J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
    Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
    Liver Int; 2004 Feb; 24(1):9-15. PubMed ID: 15101995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral features of lamivudine resistant hepatitis B genotypes A and D.
    Zöllner B; Petersen J; Puchhammer-Stöckl E; Kletzmayr J; Sterneck M; Fischer L; Schröter M; Laufs R; Feucht HH
    Hepatology; 2004 Jan; 39(1):42-50. PubMed ID: 14752821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.
    Ciancio A; Smedile A; Rizzetto M; Lagget M; Gerin J; Korba B
    Hepatology; 2004 Jan; 39(1):64-73. PubMed ID: 14752824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    J Med Virol; 2003 Jul; 70(3):355-60. PubMed ID: 12766997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission.
    Zampino R; Marrone A; Karayiannis P; Cirillo G; del Giudice EM; Rania G; Utili R; Ruggiero G
    Am J Gastroenterol; 2002 Sep; 97(9):2426-31. PubMed ID: 12358268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.